Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71.

LONDON — The French pharma company Servier said Friday that it would buy Day One Biopharmaceuticals, the maker of a drug for childhood brain tumors, in a deal worth roughly $2.5 billion. 

Servier, which is privately held, is paying $21.50 a share in cash for Day One, a roughly 68% premium on the Bay Area biotech’s closing price on Thursday. 

The deal’s centerpiece is Day One’s Ojemda, which won U.S. approval in 2024 as a treatment for pediatric low-grade glioma, the most common form of childhood brain cancer. Servier also said the deal would expand its pipeline of experimental medicines for rare cancers. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe